Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism von von Depka, Mario, Nowak-Göttl, Ulrike, Eisert, Roswith, Dieterich, Christian, Barthels, Monika, Scharrer, Inge, Ganser, Arnold, Ehrenforth, Silke

Volltext

Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A von Meunier, Sandrine, Alamelu, Jayanthi, Ehrenforth, Silke, Hanabusa, Hideji, Karim, Faraizah Abdul, Kavakli, Kaan, Khodaie, Melanie, Staber, Janice, Stasyshyn, Oleksandra, Yee, Donald L., Rageliene, Lina

Volltext

The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism von von Depka, Mario, Czwalinna, Andreas, Wermes, Cornelia, Eisert, Roswith, Scharrer, Inge, Ganser, Arnold, Ehrenforth, Silke

Volltext

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A von Giangrande, Paul, Andreeva, Tatiana, Chowdary, Pratima, Ehrenforth, Silke, Hanabusa, Hideji, Leebeek, Frank W. G., Lentz, Steven R., Nemes, Laszlo, Poulsen, Lone Hvitfeldt, Santagostino, Elena, You, Chur Woo, Ong Clausen, Wan Hui, Jönsson, Peter G., Oldenburg, Johannes

Volltext

Once‐weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9‐GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials von Oldenburg, Johannes, Carcao, Manuel, Lentz, Steven R., Mahlangu, Johnny, Mancuso, Maria Elisa, Matsushita, Tadashi, Négrier, Claude, Clausen, Wan Hui Ong, Ehrenforth, Silke, Young, Guy

Volltext

Prevalence of a 23bp Insertion in Exon 3 of the Endothelial Cell Protein C Receptor Gene in Venous Thrombophilia von Depka, Mario von, Czwalinna, Andreas, Eisert, Roswith, Wermes, Cornelia, Scharrer, Inge, Ganser, Arnold, Ehrenforth, Silke

Volltext

First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a von Hampton, Kingsley, Chowdary, Pratima, Dunkley, Scott, Ehrenforth, Silke, Jacobsen, Lotte, Neff, Anne T., Santagostino, Elena, Sathar, Jameela, Takedani, Hideyuki, Takemoto, Clifford M., Négrier, Claude

Volltext

Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors von NOWAK-GÖTTL, Ulrike, JUNKER, Ralf, KREUZ, Wolfhart, VON ECKARDSTEIN, Arnold, KOSCH, Andrea, NOHE, Natascha, SCHOBESS, Rosemarie, EHRENFORTH, Silke

Volltext

Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial von DE PAULA, ERICH V., KAVAKLI, KAAN, MAHLANGU, JOHNNY, AYOB, YASMIN, LENTZ, STEVEN R., MORFINI, MASSIMO, NEMES, LÁSZLÓ, ŠALEK, SILVA Z., SHIMA, MIDORI, WINDYGA, JERZY, EHRENFORTH, SILKE, CHUANSUMRIT, AMPAIWAN

Volltext

Prospective Evaluation of the Thrombotic Risk in Children With Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothro... von Nowak-Göttl, Ulrike, Wermes, Cornelia, Junker, Ralf, Koch, Hans-Georg, Schobess, Rosmarie, Fleischhack, Gudrun, Schwabe, Dirk, Ehrenforth, Silke

Volltext

Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism von von Depka, Mario, Nowak-Göttl, Ulrike, Eisert, Roswith, Dieterich, Christian, Barthels, Monika, Scharrer, Inge, Ganser, Arnold, Ehrenforth, Silke

Volltext

Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothro... von NOWAK-GÖTTL, U, WERMES, C, JUNKER, R, KOCH, H.-G, SCHOBESS, R, FLEISCHHACK, G, SCHWABE, D, EHRENFORTH, S

Volltext

Prothrombin G20210A Gene Mutation and Further Prothrombotic Risk Factors in Childhood Thrombophilia von Junker, Ralf, Koch, Hans-Georg, Auberger, Karin, Münchow, Nicole, Ehrenforth, Silke, Nowak-Göttl, Ulrike

Volltext

Safety and Preliminary Efficacy of Recombinant Activated FVII Analog (NN1731) In the Treatment of Joint Bleeds In Congenital Hemophilia Patients with Inhibitors von Paula, Erich de, Kavakli, Kaan, Mahlangu, Johnny, Ayob, Yasmin, Lentz, Steven R., Morfini, Massimo, Nemes, László, Salek, Silva Zupancic, Shima, Midori, Windyga, Jerzy, Ehrenforth, Silke, Andersen, Henning Friis, Chuansumrit, Ampaiwan

Volltext

Immunogenicity Lessons Learned from the Clinical Development of Vatreptacog Alfa, A Recombinant Activated Factor VII Analog, in Hemophilia with Inhibitors von Lamberth, Kasper, Weldingh, Karin Nana, Ehrenforth, Silke, Chéhadé, Mette Ribel, Østergaard, Henrik

Volltext

Inhibitor Development in Previously Untreated Patients with Hemophilia A: A Prospective Long-Term Follow-Up Comparing Plasma-Derived and Recombinant Products von Kreuz, Wolfhart, Ettingshausen, Carmen Escuriola, Zyschka, Alex, Oldenburg, Johannes, Saguer, Inmaculada Martinez, Ehrenforth, Silke, Klingebiel, Thomas

Volltext

rFVIIa Treatment and Efficacy Prediction in a Patient with Hermansky-Pudlak Syndrome Type 1 (HPS-1) Using Global Clotting Tests and Flow Cytometry von Wegert, Wolfgang, Scholz, Thomas, Ehrenforth, Silke, Mondorf, Wolfgang, Kirchmaier, Carl M.

Volltext

Liver Damage Induced by Coumarin Anticoagulants von Ehrenforth, Silke, Schenk, Joachim F., Scharrer, Inge

Volltext

Inhibitor development in previously untreated patients with hemophilia A: A prospective long-term follow-up comparing plasma-derived and recombinant products: Recombinant factor VI... von KREUZ, Wolfhart, ESCURIOLA ETTINGSHAUSEN, Carmen, ZYSCHKA, Alex, OLDENBURG, Johannes, MARTINEZ SAGUER, Inmaculada, EHRENFORTH, Silke, KLINGEBIEL, Thomas

Volltext

Factor VIII Inhibitors in Patients with Hemophilia A: Epidemiology of Inhibitor Development and Induction of Immune Tolerance for Factor VIII von Kreuz, Wolfhart, Becker, Sabine, Lenz, Elisabeth, Martinez-Saguer, Inmaculada, Escuriola-Ettingshausen, Carmen, Funk, Markus, Ehrenforth, Silke, Auerswald, Günther, Kornhuber, Bernhard

Volltext